✨ Free AI Report
Erasca, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Erasca, Inc.
Company Research

Erasca, Inc.: Business Overview, Financials & Competitive Analysis

Erasca, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Erasca offers promising early-stage oncology assets targeting a massive TAM with validated biology and favorable clinical signals, though dependent on achieving clinical/regulatory milestones. Early clinical data shows encouraging efficacy signals across multiple tumor types, with confirmed partial responses at low doses and favorable safety profiles with no dose-limiting toxicities. ERAS-0015.

What is Erasca, Inc.'s industry? Erasca, Inc. (erasca.com) operates in Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting. AskCyborg classifies Erasca, Inc. under Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting in its company registry.

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The RAS/MAPK pathway is linked to approximatel...

7/ 10Strong

Cyborg Score thesis

Erasca offers promising early-stage oncology assets targeting a massive TAM with validated biology and favorable clinical...

Read the full analyst-debate transcript →
Industry Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Erasca, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Erasca, Inc.

AskCyborg analysts argue the bull and bear cases for Erasca, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Erasca, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Erasca, Inc. Overview

Pro stress-test →

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The RAS/MAPK pathway is linked to approximately 5.5 million new cases of cancer per year worldwide, over 90% of which have limited or no treatment options. Erasca is advancing a pipeline of oral targeted therapies designed to address this massive unmet medical need.

Strategic Profile

Pro stress-test →

The company's strategy combines a pan-RAS molecular glue and a pan-KRAS inhibitor, giving exposure to different "swim lanes" that could emerge across tumor types and treatment settings. With a strong cash position of $411 million as of March 31, 2025, the company has operational funding through the second half of 2028. In January 2026, Erasca completed an upsized public offering of 25,875,000 shares, raising $225 million, further strengthening its financial runway.

Competitive Landscape

Pro stress-test →

Erasca has strategic partnerships with Novartis (naporafenib co-development), Katmai Pharmaceuticals (ERAS-801), and NiKang Therapeutics (ERAS-601). The molecular glue space is competitive, with RevMed's RMC-6236 as a benchmark program. Erasca's ERAS-0015 demonstrates superior binding affinity and dosing advantages versus RMC-6236 preclinically.

Industry Context

Erasca, Inc. operates in Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting.

Key facts

Founded: 2018 · Headquarters: San Diego, California · Revenue: $0

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Erasca, Inc..

  • Dose escalation in the Phase I AURORAS-1 study of ERAS-0015 is progressing faster than anticipated, with enrollment momentum supporting rapid advancement through multiple dose levels.
  • Erasca raised $225 million in January 2026 through an upsized public offering, demonstrating strong investor confidence in its RAS-targeted pipeline.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Completed upsized public offering of $225 million to fund pipeline advancement
  • January 2026Reported positive early Phase 1 data for ERAS-0015 showing confirmed partial responses and favorable safety profile
  • +1 moreTrack every material event for Erasca, Inc. as it happens. Explore monitoring →
Get alerted when Erasca, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RMC-6236Pan-RAS molecular glue in clinical development→KRAS inhibitorsKRAS-selective small molecule inhibitors approved or late-stage→Other RAS pathway inhibitorsMEK, ERK, and other MAPK pathway targeting approaches→

Compare Erasca, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Erasca, Inc. operates in Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting research →
NEW · MCP server

Ask your AI assistant about Erasca, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Erasca, Inc. and its top competitor on Cyborg Score”
“What did Erasca, Inc. do this quarter?”
“Is Erasca, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Erasca, Inc. do?+
Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The RAS/MAPK pathway is linked to approximatel...
What is Erasca, Inc.'s Cyborg Score?+
Erasca, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Erasca, Inc.'s main competitors?+
Named competitors include RMC-6236, KRAS inhibitors, Other RAS pathway inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Erasca, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Erasca, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Erasca, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Revolution Medicines, Inc.8Tyra Biosciences, Inc.6Acrivon Therapeutics, Inc.5Personalis, Inc.4PMV Pharmaceuticals, Inc.